(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 15.93% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Adma Biologics's revenue in 2026 is $512,275,000.On average, 7 Wall Street analysts forecast ADMA's revenue for 2026 to be $127,823,577,182, with the lowest ADMA revenue forecast at $116,315,244,324, and the highest ADMA revenue forecast at $149,341,785,390. On average, 7 Wall Street analysts forecast ADMA's revenue for 2027 to be $152,240,147,149, with the lowest ADMA revenue forecast at $131,689,552,759, and the highest ADMA revenue forecast at $182,386,245,230.
In 2028, ADMA is forecast to generate $178,782,331,729 in revenue, with the lowest revenue forecast at $145,551,964,604 and the highest revenue forecast at $222,483,982,644.